Michael H Belcourt

US Patent:

7405317, Jul 29, 2008

Filed:

Sep 21, 2005

Appl. No.:

11/232252

Inventors:

Xu Lin - Branford CT, US
Ivan King - North Haven CT, US
Michael F. Belcourt - Wallingford CT, US
Terrence W. Doyle - Killingworth CT, US

Assignee:

Vion Pharmaceuticals Inc. - New Haven CT

International Classification:

C07F 9/22
C07C 313/04
C07C 313/06

US Classification:

558 61, 562 8, 558154, 558193, 558190

Abstract:

Novel phosphate-bearing prodrugs of sulfonyl hydrazines have the formula presented below. Pharmaceutical compositions and uses thereof in the treatment of cancer are claimed. The aforementioned prodrugs include enantiomers, stereoisomers and tautomers thereof, as well as pharmaceutically acceptable salts or solvates and metabolites from all stages. The aforementioned prodrugs are preferentially activated in hypoxic tumors and can be given either alone, or in combination with other anticancer agents or with phototheraphy or radiotherapy.

US Patent:

7452531, Nov 18, 2008

Filed:

Mar 17, 2005

Appl. No.:

11/082544

Inventors:

David G. Bermudes - Wallingford CT, US
Ivan C. King - New Haven CT, US
Caroline A. Clairmont - Cheshire CT, US
Michael Belcourt - Wallingford CT, US

Assignee:

Vion Pharmaceuticals, Inc. - New Haven CT

International Classification:

A01N 63/00

US Classification:

424 932, 424 931, 424 934

Abstract:

The present application discloses the preparation and use of attenuated tumor-targeted bacteria vectors for the delivery of one or more primary effector molecule(s) to the site of a solid tumor. The primary effector molecule(s) of the invention is used in the methods of the invention to treat a solid tumor cancer such as a carcinoma, melanoma, lymphoma, or sarcoma. The invention relates to the surprising discovery that effector molecules, which may be toxic when administered systemically to a host, can be delivered locally to tumors by attenuated tumor-targeted bacteria with reduced toxicity to the host. The application also discloses to the delivery of one or more optional effector molecule(s) (termed secondary effector molecules) which may be delivered by the attenuated tumor-targeted bacteria in conjunction with the primary effector molecule(s).

US Patent:

7605137, Oct 20, 2009

Filed:

Mar 25, 2005

Appl. No.:

10/593217

Inventors:

Ivan King - North Haven CT, US
Mario Sznol - Woodbridge CT, US
Michael Belcourt - Wallingford CT, US

Assignee:

Vion Pharmaceuticals, Inc. - New Haven CT

International Classification:

A61K 31/175
A61K 31/52
A61K 31/505

US Classification:

514 43, 514 45, 514 46, 514 50, 514 86, 514274, 564 35

Abstract:

This invention provides a method for treating tumor in a subject comprising administering to the subject an effective amount of: (1) VNP40101M, or its equivalent; and (2) a nucleoside, or a nucleoside analog. This invention also provides a method for inhibiting tumor cell growth comprising contacting the tumor cell with effective amounts of: (1) VNP40101M, or its equivalent; and (2) a nucleoside, or a nucleoside analog. The present invention relates to the treatment of cancer, comprising administering to a subject in need thereof an effective amount of VNP40101M in combination with a nucleoside.

US Patent:

20090075945, Mar 19, 2009

Filed:

Apr 2, 2008

Appl. No.:

12/080357

Inventors:

Xu Lin - Branford CT, US
Ivan King - North Haven CT, US
Michael F. Belcourt - Wallingford CT, US
Terrence W. Doyle - Killingworth CT, US

Assignee:

Vion Pharmaceuticals, Inc. - New Haven CT

International Classification:

A61K 31/662
A61P 35/00

US Classification:

514117

Abstract:

Novel phosphate-bearing prodrugs of sulfonyl hydrazines have the formula presented below. Methods of treatment of cancer are claimed. The aforementioned prodrugs include enantiomers, stereoisomers and tautomers thereof, as well as pharmaceutically acceptable salts or solvates and metabolites from all stages. The aforementioned prodrugs are preferentially activated in hypoxic tumors and can be given either alone, or in combination with other anticancer agents or with phototheraphy or radiotherapy.where R is C-Calkyl or haloalkyl;R′ and R″ are each independently C-Calkyl; andRis C-Calkyl,or a pharmaceutically acceptable salt, solvate, polymorph or metabolite thereof.

US Patent:

20090169517, Jul 2, 2009

Filed:

Oct 20, 2008

Appl. No.:

12/254122

Inventors:

David G. Bermudes - Wallingford CT, US
Ivan C. King - New Haven CT, US
Caroline A. Clairmont - Cheshire CT, US
Stanley I. Lin - Madison CT, US
Michael Belcourt - Wallingford CT, US

International Classification:

A61K 35/74
C12N 1/21

US Classification:

424 934, 4352523

Abstract:

The present application discloses the preparation and use of attenuated tumor-targeted bacteria vectors for the delivery of one or more primary effector molecule(s) to the site of a solid tumor. The primary effector molecule(s) of the invention is used in the methods of the invention to treat a solid tumor cancer such as a carcinoma, melanoma, lymphoma, or sarcoma. The invention relates to the surprising discovery that effector molecules, which may be toxic when administered systemically to a host, can be delivered locally to tumors by attenuated tumor-targeted bacteria with reduced toxicity to the host. The application also discloses to the delivery of one or more optional effector molecule(s) (termed secondary effector molecules) which may be delivered by the attenuated tumor-targeted bacteria in conjunction with the primary effector molecule(s).

US Patent:

6962696, Nov 8, 2005

Filed:

Aug 24, 2000

Appl. No.:

09/645415

Inventors:

David G. Bermudes - Wallingford CT, US
Ivan C. King - New Haven CT, US
Caroline A. Clairmont - Cheshire CT, US
Stanley L. Lin - Madison CT, US
Michael Belcourt - Wallingford CT, US

Assignee:

Vion Pharmaceuticals Inc. - New Haven CT

International Classification:

A01N063/00
C12N015/63
C12N001/20
G01N033/569

US Classification:

424 934, 4353201, 4352528, 435 735

Abstract:

The present application discloses the preparation and use of attenuated tumor-targeted bacteria vectors for the delivery of one or more primary effector molecule(s) to the site of a solid tumor. The primary effector molecule(s) of the invention is used in the methods of the invention to treat a solid tumor cancer such as a carcinoma, melanoma, lymphoma, or sarcoma. The invention relates to the surprising discovery that effector molecules, which may be toxic when administered systemically to a host, can be delivered locally to tumors by attenuated tumor-targeted bacteria with reduced toxicity to the host. The application also discloses to the delivery of one or more optional effector molecule(s) (termed secondary effector molecules) which may be delivered by the attenuated tumor-targeted bacteria in conjunction with the primary effector molecule(s).